Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Syntara Limited ( (AU:SNT) ).
Syntara Limited, an ASX‑listed clinical‑stage biotechnology company, develops novel drugs targeting extracellular matrix dysfunction for blood cancers, inflammation and fibrosis, with a portfolio that includes amsulostat for myelofibrosis and myelodysplastic syndrome, topical pan‑LOX inhibitors for hypertrophic and keloid scars, and SNT‑4728 for neuroinflammatory sleep and neurodegenerative disorders.
The company has received an approximately A$1.7 million milestone payment from Parkinson’s UK after dosing the final patient in its Phase 2 trial of SNT‑4728 in individuals with isolated REM sleep behaviour disorder, a strong early indicator of Parkinson’s disease and related dementias.
Top‑line safety and efficacy data from the study are due in the second quarter of calendar 2026, with a further A$0.45 million milestone payable on project completion, underscoring external support for SNT‑4728 and Syntara’s positioning in an addressable market estimated at US$1.6 billion for iRBD and US$9.2 billion for Parkinson’s disease by 2030.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is an ASX‑listed, clinical‑stage drug development company focused on targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry and related technologies. Its pipeline spans novel treatments for blood cancers, inflammation and fibrosis, including lead candidate amsulostat for myelofibrosis, pan‑LOX inhibitors for scarring, and SNT‑4728 for neuroinflammatory sleep and neurodegenerative disorders.
The company is advancing multiple early‑ and mid‑stage clinical programs in myelofibrosis, myelodysplastic syndrome and fibrotic skin conditions, alongside preclinical candidates for kidney, liver, pulmonary and cardiac fibrosis. Based in Sydney and listed under the ticker SNT, Syntara has previously commercialised and sold two respiratory products, Bronchitol and Aridol, and is now concentrating on its expanded drug pipeline in oncology, fibrosis and neurology.
Average Trading Volume: 1,160,213
Technical Sentiment Signal: Sell
Current Market Cap: A$50.66M
See more insights into SNT stock on TipRanks’ Stock Analysis page.